NCT02319512

Brief Summary

The purpose of this study is to determine whether the use of chewing gum effects postoperative ileus after pancreaticoduodenectomy.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jan 2012

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2013

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

December 7, 2014

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 18, 2014

Completed
Last Updated

December 18, 2014

Status Verified

December 1, 2014

Enrollment Period

1.8 years

First QC Date

December 7, 2014

Last Update Submit

December 13, 2014

Conditions

Outcome Measures

Primary Outcomes (2)

  • First flatus after surgery

    From day of surgery until first postoperative flatus (with in the first 21 days)

  • First stool after surgery

    From day of surgery until first stool (with in the first 21 days)

Secondary Outcomes (3)

  • Start of clear fluids

    From day of surgery until start of clear liquids after surgery (with in the first 21 days)

  • Start of liquid diet

    From day of surgery until start of liquid diet after surgery (with in the first 21 days)

  • Length of hospital stay

    From day of surgery until discharge from surgical ward (with in the first 21 days)

Study Arms (2)

Chewing gum

EXPERIMENTAL

Chewing gum was administered every fourth hour (08.00-12.00, 12.00-16.00 and 16.00-20.00). During each four-hour period, patients chewed two pieces of gum for 30 minutes each. Chewing gum was used during the whole hospital stay.

Other: Chewing gum

Control

SHAM COMPARATOR

Controls received standard care and sips of glucose, in total 3.6g/day in a 12-ml mixture per day, the same amount of glucose per day as the treatment group received via the chewing gum

Other: Glucose

Interventions

ChiczaTM organic chewing gum 6 pieces a day

Chewing gum
GlucoseOTHER

12ml glucose solution (13,6g) per day

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with pancreatic or periampullary cancer and scheduled to undergo pancreaticoduodenectomy.
  • Understand and speak swedish
  • No diagnosed neurological injuries or diseases affecting the ability to swallow or gastric function
  • No ongoing treatment for mental disease
  • No ongoing abuse of alcohol or other drugs
  • No previously known allergies to the content of chewing gum

You may not qualify if:

  • Additional surgery after primary surgery.
  • No radical curative surgery
  • Previous abdominal surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Andersson T, Bjersa K, Falk K, Olsen MF. Effects of chewing gum against postoperative ileus after pancreaticoduodenectomy--a randomized controlled trial. BMC Res Notes. 2015 Feb 10;8:37. doi: 10.1186/s13104-015-0996-0.

MeSH Terms

Interventions

Chewing GumGlucose

Intervention Hierarchy (Ancestors)

Plant GumsBiopolymersPolymersMacromolecular SubstancesPolysaccharidesCarbohydratesPlant ExudatesBiological ProductsComplex MixturesCandyFoodDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesHexosesMonosaccharidesSugars

Study Officials

  • Kristin Falk, PhD

    Institute of Health and Care Sciences, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden

    STUDY DIRECTOR
  • Monika Fagevik Olsén, PhD

    Department of Gastrosurgical Research and Education, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden

    STUDY DIRECTOR
  • Kristofer Bjerså, PhD

    Division of Nursing, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

    PRINCIPAL INVESTIGATOR
  • Thomas Andersson, MSc

    Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
RN, CNS, MSc

Study Record Dates

First Submitted

December 7, 2014

First Posted

December 18, 2014

Study Start

January 1, 2012

Primary Completion

November 1, 2013

Study Completion

December 1, 2013

Last Updated

December 18, 2014

Record last verified: 2014-12